22 Jan 2009
3i appoints John J Moore Jr to global healthcare leadership team
John will be responsible of 3i’s healthcare investment strategy across North America. He joins a team of more than 30, 3i healthcare professionals operating from 14 countries within North America, Europe and Asia. 3i’s global healthcare team has invested approximately $2bn in over 36 healthcare companies since 2001. John’s appointment completes 3i’s global healthcare leadership team, which is led by Alan Mackay in London.
John brings extensive healthcare experience to 3i. He joins after 15 years with Morgan Stanley where as a Managing Director and the Global Head of Healthcare Investment Banking, he was responsible for all aspects of Morgan Stanley’s healthcare banking efforts around the world.
“We are pleased to have John join 3i as we continue our expansion in North America,” said Ken Hanau, Partner, Head of 3i North America. “Healthcare is a major area of focus for 3i and with his expertise, knowledge and enthusiasm; John will be a great addition to the team.”
Alan Mackay, Global lead partner, Healthcare added: “We already have great healthcare partners in Europe and Asia and the addition of John to 3i’s team makes us a truly global player in healthcare private equity. Our global perspective and local networks allow 3i to invest strategically to further our growth while providing unique and valuable insights to our portfolio companies. ”
3i’s recent healthcare global investments include: minority investment in Quintiles, world’s leading provider of clinical research outsourcing (CRO) solutions, offering clinical drug development services to pharma and biotech clients and €140m (around US$223m) for a minority stake in Labco, a leading pan European medical diagnostics network
Notes to editors
Biography of John J. Moore, Jr.
A 15 year veteran of Morgan Stanley and as a Managing Director and the Global Head of Healthcare Investment Banking, John was responsible for all aspects of Morgan Stanley’s healthcare banking efforts around the world.
During his 15 years at Morgan Stanley, John has worked with companies in the medical technology, emerging pharma and healthcare services sectors on over one hundred transactions ranging from mergers, acquisitions and spin-outs to initial public offerings, financings and principal investments.
In addition to healthcare, John has also covered the consumer, retail and general industrial sectors. He is a graduate of Harvard College and Stanford Law School, a member of the Rockefeller University Council, the former president of the Irvington Institute for Immunological Research and a member of the Council on Foreign Relations.
About 3i
3i is an international leader in private equity. We focus on Buyouts, Growth Capial, Infrastructure and Quote Private Equity ("QPE") and invest across North America, Europe and Asia. Our competitive advantage comes from our international network and the strength and breadth of our business relationships. These underpin the value that we deliver to our portfolio and to our shareholders.
3i''s healthcare team has invested over €1.6bn in 36 healthcare companies since April 2001* across Europe, North America and Asia. We invest in Pharmaceuticals, Medical Technology and Healthcare Services companies led by managment teams with a strong track record and the ambition to build lasting value.
3i''s recent investments in the healthcare sector include: Qunitiles Transntional, Axellia (formerly Alpharma API), LHi Technology and Ultralase.
For further information please contact:
Leonie Foster
email. Leonie.Foster@3i.com
tel. +44207 975 3044
